- Home
- SGMT vs ABOS Comparison
SGMT vs ABOS Comparison
Compare SGMT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | ABOS |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 155.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGMT | ABOS |
|---|---|---|
| Price | $6.43 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $26.38 | $8.00 |
| AVG Volume (30 Days) | 396.0K | ★ 511.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.36 | $0.95 |
| 52 Week High | $11.41 | $3.60 |
Technical Indicators
Market Signals| Indicator | SGMT | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 56.96 |
| Support Level | $6.30 | $2.19 |
| Resistance Level | $6.72 | $3.05 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 90.69 | 85.62 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.